Navigation Links
A New Approach to Manage Opiate Addiction

Withdrawal symptoms like severe pain, nausea, agitation and sweats motivate addicts to continue taking drugs. The findings// of a new study suggest new approaches to reduce withdrawal symptoms.

A new study finds that disrupting the brain's stress-response mechanism exacerbates behavioral withdrawal symptoms in mice, and that giving the mice the hormone corticosterone alleviates those symptoms.

Angelo Contarino of Université Victor Segalen Bordeaux 2 and colleagues published their findings in the February 15, 2007 issue of the journal Neuron, published by Cell Press.

In their studies, the researchers mimicked the pattern of opiate addiction and withdrawal in mice that were genetically deficient in a receptor called CRF1. Receptors are proteins on the cell surface that trigger reactions in the cell when activated.

CRF1 is a trigger for the corticotrophin-releasing factor system in the brain and is an essential protein for coping with stressful events. In mimicking addiction and withdrawal, the researchers gave the mice increasing doses of morphine and then stopped morphine administration to induce withdrawal symptoms.

The researchers found that the CRF1-deficient mice showed more severe and prolonged behavioral symptoms of withdrawal—such as jumping and "wet dog shaking"—when compared with normal mice as had been shown previously. Similarly, when the researchers administered a drug that blocks the receptor in normal mice, they saw the same aggravating effects.

The researchers also detected genetic changes in the brains of the mice, which indicated that the stress-response circuitry in the brain was impaired.

However, Contarino and colleagues found that giving the mice the steroid hormone corticosterone abolished the difference in withdrawal symptoms between the CRF1-deficient and normal mice. The hormone also restored the normal stress-response-related genetic activity in the brain, they found.

'"/>




Page: 1 2

Related medicine news :

1. New Dietary Approach To Manage Kidney Stones
2. Approaching through Telemedicine benefits patients
3. Gel Offers A More Targeted Approach
4. New Cost Effective Approach To Promote Sun Protection
5. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
6. A New Approach In Treatment Neurogenic Detrusor Overactivity In Children
7. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
8. Lazy Eye Can Be Effectively Treated By New Approach
9. Novel Approach to Identify Protein Links with Genetic Disorder
10. NHS To Be Reformed By Using A Hybrid Approach
11. Two-In One Approach To Prevent Incontinence After Prolapse Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Approach Manage Opiate Addiction

(Date:12/2/2008)...tCall/ -- Quest Diagnostics Incorporated (NYSE: ...testing, information and services, announced that ...thcare Conference in New York City today, December...cheduled to begin at 4:00 p.m. Eastern Time. , ...affirm its 2008 guidance for revenue growth of gre...
(Date:12/2/2008)...er with aprotinin, a drug commonly used to control...y, compared with lysine analogues, according to a ...9 to be published in the January 20th issue of C...dvisory panel will meet to decide on aprotinin use...the meeting. , The study, a systematic review o...
(Date:12/2/2008)...rstCall/ - NUCRYST Pharmaceuticals Corp., a develo...t infection and inflammation, announced today that...rity shareholder, The Westaim Corporation ("Westai...areholders to consider a return of capital of US$0...s to a return of capital of approximately US$15 mi...
(Date:12/2/2008)...e Efficacy of Commercially Available Hypomethylati... Eisai Corporation of North Americ...rst clinical trial evaluating the activity of Daco...za(R) (azacitidine) in adult patients with interme...ic syndromes (MDS), a potentially life-threatening...
Breaking Medicine News(10 mins):Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
... of Public Health have reported that over the coun...eneficial as they can lower the risk of Parkinson’... took daily one ibuprofen tablet, men and women, f...eople seemed to have a 38% less chance of having P...
... increased calcium intake by drinking milk or othe...of Parkinson’s disease. Parkinson’s disease is a d...s are muscle tremors, muscle rigidity, decreased m...low voluntary movements, and a mask-like facial ex...
... out how to elevate the functional limitations of ...e researchers of Feinberg School of Medicine, US ...and old with arthritis. Functions, which were chec...ng to daily living and specialized activities of d...
...ncy is associated with dental problems. But are th...trong enough to affect the babies’ birth weight or...ew York University College of Dentistry, US, say t...a affect the pregnancy by causing pre-term deliver...
Other Medicine News:
(Date:12/1/2008)...e Call Scheduled for Tuesday, December 9 at 11:00 ..., , SOUTH SAN FRANCISCO, Calif., Dec. 1 /...Inc. (Nasdaq: SNSS ), a biopharmaceutical compan... of new oncology therapeutics, today announced new...id leukemia (AML) will be presented during the 50t...
(Date:11/28/2008)..., Germany, November 28 German biot...ship in specialized HIV monitoring and,AIDS patie...ng countries. In,the year 2008, 2.5 million patie...obust and highly affordable "CyFlow" system, suppo...ith HIV/AIDS. Due to introduction of the,Partec i...
(Date:11/26/2008)...ed to 406 Subjects , , FRANKLIN, Mass., Nov...TC Bulletin Board: PLCSF) announced today that it ...Drug Administration (FDA) for its U.S. pivotal tri...alGuard System(TM) and associated therapy in the ..., , The FDA also approved PLC,s request to ...
(Date:11/25/2008)...ANCISCO, Calif., Nov. 25 ... a biopharmaceutical company focused on,innovativ... be exploring,strategic alternatives for its prec...ompany to focus its resources on the clinical deve..., and to support the initial commercialization of,...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 1STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 2STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 3SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 1SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 2SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 3The ABCs of childhood zs 3A Snoring may be chronic despite surgery 14382 1The ABCs of childhood zs 3A Snoring may be chronic despite surgery 14382 2Low exposure to asbestos like mineral from Montana vermiculite may up lung disease risk 2504 1Low exposure to asbestos like mineral from Montana vermiculite may up lung disease risk 2504 2
...ll/ - Research,collaborators with Oncolytics Biote...poster presentation covering REOLYSIN(R),clinical ...ology,(ASCO) Annual Meeting, to be held June 1-5, ...ncolytics, U.K. Phase I systemic,administration tr...ase I Study of,Wild-Type Oncolytic Reovirus Admini...
...007 - A therapeutic,vaccine developed by the Germa...ew hope for cancer patients. The results of a,succ...d to an,international audience at the Annual Confe...y (ASCO) in Chicago, USA. ASCO is the,most importa...,world-wide., The active substance VPM4001, an imm...
Other Medicine Technology:Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: